Cargando…

Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib in Brazilian patients from Phase 2 (P2) and Phase 3 (P3) global studies of up to 24 months’ duration were evaluated. METHODS: Data were pooled from Brazilian p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lomonte, Andrea B.V., Radominski, Sebastião C., Marcolino, Flora M.D., Brenol, Claiton V., Zerbini, Cristiano A.F., García, Erika G., Akylbekova, Ermeg L., Rojo, Ricardo, de Leon, Dario Ponce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081087/ https://www.ncbi.nlm.nih.gov/pubmed/30075534 http://dx.doi.org/10.1097/MD.0000000000011609

Ejemplares similares

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
por: Hall, Stephen, et al.
Publicado: (2018)

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses
por: Strand, Vibeke, et al.
Publicado: (2018)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease?
por: Biemans, Vince BC, et al.
Publicado: (2020)

Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases
por: Sanachai, Kamonpan, et al.
Publicado: (2020)

Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib
por: Yamamura, Yuriko, et al.
Publicado: (2019)

Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing
por: Gaber, Timo, et al.
Publicado: (2020)

Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib
por: Kim, Sa Rang, et al.
Publicado: (2018)

Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats
por: Gwak, Eun Hye, et al.
Publicado: (2020)

Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient
por: Berbert Ferreira, Sineida, et al.
Publicado: (2021)

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
por: Curtis, Jeffrey R, et al.
Publicado: (2016)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Proper management of rheumatoid arthritis in Latin America. What the guidelines say?
por: Brenol, Claiton V., et al.
Publicado: (2015)

Erratum to: Proper management of rheumatoid arthritis in Latin America. What the guidelines say?
por: Brenol, Claiton V., et al.
Publicado: (2015)

Funcionality assessed by the core set of the international classification of functionality and health for rheumatoid arthritis: A cohort study
por: Portes, Juliana, et al.
Publicado: (2023)

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight
por: Hutmacher, MM, et al.
Publicado: (2017)

Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis
por: Talty, Ronan, et al.
Publicado: (2021)

Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China
por: Zhang, Junmei, et al.
Publicado: (2023)

A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib
por: Aleisa, Ahmad I., et al.
Publicado: (2020)

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
por: Hasni, Sarfaraz A., et al.
Publicado: (2021)

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
por: Tan, H, et al.
Publicado: (2013)

Idiopathic erythema multiforme: Evidence of underlying Janus kinase–signal transducer and activator of transcription activation and successful treatment with tofacitinib
por: Damsky, William, et al.
Publicado: (2016)

Various Application of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
por: Sadeghi, Sara, et al.
Publicado: (2022)

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
por: Charles-Schoeman, Christina, et al.
Publicado: (2016)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
por: Nash, Peter, et al.
Publicado: (2018)

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial
por: Papp, Kim A., et al.
Publicado: (2016)

Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
por: Morelli, Martina, et al.
Publicado: (2018)

Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report
por: Komeda, Yoriaki, et al.
Publicado: (2020)

Tofacitinib
Publicado: (2012)

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
por: Ports, WC, et al.
Publicado: (2013)

Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report
por: Li, Ben, et al.
Publicado: (2020)

Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program
por: Lichtenstein, Gary R, et al.
Publicado: (2020)

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
por: Yamanaka, Hisashi, et al.
Publicado: (2016)

Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients
por: Shivanna, Chandrashekar Byalekere, et al.
Publicado: (2018)

Rheumatoid arthritis in Latin America: the importance of an early diagnosis
por: da Mota, Licia Maria Henrique, et al.
Publicado: (2015)

Cross-cultural and clinical validation of the MDHAQ/RAPID3 questionnaire in electronic format for a Brazilian population of patients with rheumatoid arthritis
por: Lineburger, Ilka Benedet, et al.
Publicado: (2022)

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
por: Guimarães, Patrícia O., et al.
Publicado: (2021)

Erratum to Tofacitinib
Publicado: (2012)

Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials
por: Strober, B.E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dr2u0j8oas76usin4dc3me4alj